Significance and control of cardiac arrhythmias in patients with congestive cardiac failure

Heart Failure Reviews

Volumn 7, Issue 3, 2002, Pages 285-300

  Singh, Bramah N ^a  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

Amiodarone; Atrial fibrillation; Beta blockers; Cardiac failure and arrhythmias; Dofetilide; Sudden death; Ventricular tachycardia and fibrillation

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; AZIMILIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISOPYRAMIDE; DIURETIC AGENT; DOFETILIDE; DRONEDARONE; FLECAINIDE; IBUTILIDE; INOTROPIC AGENT; METOPROLOL; PLACEBO; PROCAINAMIDE; PROPAFENONE; PROPRANOLOL; QUINIDINE; SODIUM CHANNEL BLOCKING AGENT; SOTALOL; SPIRONOLACTONE; VASODILATOR AGENT; VERAPAMIL;

ANTIARRHYTHMIC ACTIVITY; BETA ADRENERGIC RECEPTOR BLOCKING; CARDIOVERSION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEFIBRILLATOR; DISEASE CONTROL; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CLASSIFICATION; DRUG EFFECT; DRUG METABOLISM; DRUG POTENTIATION; DRUG USE; EUROPE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART PROARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HIGH RISK PATIENT; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MITRAL VALVE DISEASE; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PREVALENCE; PROPHYLAXIS; QUALITY OF LIFE; RESUSCITATION; REVIEW; SIDE EFFECT; SINUS RHYTHM; SUDDEN DEATH; SUPRAVENTRICULAR TACHYCARDIA; SYMPTOM; TORSADE DES POINTES; UNITED STATES;

ADRENERGIC BETA-ANTAGONISTS; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; DRUG THERAPY, COMBINATION; HEART FAILURE, CONGESTIVE; HUMANS; PHENETHYLAMINES; SULFONAMIDES; TACHYCARDIA, VENTRICULAR; VENTRICULAR FIBRILLATION;

EID: 0036660392     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020001912248     Document Type: Review

References (97)

1. Francis GS. Development of arrhythmias in patients with congestive heart failure: Pathophysiology, prevalence, and prognosis. Am J Cardiol 1986;87:3B-10B.
2. Coleman HN, Taylor RR, Pool PE, Wipple GH, Covell JN, Ross JR, Braunwald E. Congestive heart failure following chronic tachycardia. Am Heart J 1971;81:750-798.
3. Grogan M, Smith HC, Gersh BL, Wood DL. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol 1992;69:1570-1573.
4. Bigger JT Jr. Why patients with congestive heart failure die: Arrhythmias and sudden cardiac death. Circ 1987;75 (Suppl IV):28-35.
5. Guido J, Bues Genis A, Dominguez de Rozas JM, Fiol M, Vinolas X, Bayes de Luna A. Sudden death in heart failure. Heart Failure Reviews 1997;1:249-260.
6. CIBIS II Investigators and Committes. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): A randomized trial. Lancet 1999;353:9-13.
7. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Interventional Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-2007.
8. Packer M, Coats AJS, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL, for the Carvedilol Prospective Randomized Cumulative Survival Study Group. N Eng J Med 2001;344:1651-1658.
9. Pfeffer MA, Braunwald E, Moyu LAS, et al. on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992;327:685-692.
10. Kjekshus J. Arrhythmias and mortality in congestive heart failure. Amer J Cardiol 1990;65:1-42.
11. Luu M, Stevenson WG, Stevenson LW, Baron K, Warden J. Diverse mechanisms of unexpected cardiac arrests in advanced heart failure. Circ 1989;80:1675-1680.
12. Chakko CS, Georghiade M. Ventricular arrhythmias in patients with congestive heart failure: Incidence, significance, and effectiveness of antiarrhythmic therapy. Am Heart J 1985;109:497-504.
13. Cohn JN, Archibald DG, Ziesche S, Francoisa JA, Harston WE, Tristani FE, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1996;314:1547-1552.
14. Cohn JN. Structural basis for heart failure: Ventricular remodelling and its pharmacologic inhibition. Circ 1995;91:2504-2507.
15. Eckberg DL, Drabinsky M, Braunwald E. Defective cardiac parasympathetic control of patients with heart disease. N Eng J Med 1971;285:877-883.
16. Janse MJ, de Bakker JMT, Opthof T. Pathogenesis of ventricular arrhythmias in heart failure. In: Brachmann J, Dietz R, Kubler W, eds. Heart Failure and Arrhythmias. Berlin: Springer Verlag, 1990:16-23.
17. Brown MJ, Brown DC, Murphy MB. Hypokalemia from beta-2 receptor stimulation by circulating epinephrine. N Eng J Med 309:1414-1419.
18. Damiano JR, Tripp HF, Small KW, Asano T, Jones RH, Lowe JE. The functional consequences of prolonged supraventricular tachycardia. J Am Coll Cardiol 1985;5:541-547.
19. Marban E. Molecular approaches to arrhythmogenesis. In: Chien K, ed. Molecular Basis of Heart Disease. New York: W.B. Saunders, 1998.
20. Tomaselli FG, Rosen J. Molecular aspects of arrhythmias associated with cardiomyopathies. Curr Opin Cardiol 2000;15:202-208.
21. Potreau D, Gomez JP, Fares N. Depressed transient outward current in single hypertrophied cardiomyocytes isolated from the right ventricle of ferret heart. Cardiovasc Res 1995;30:440-448.
22. Thuringer D, Coulombe A, Derubaix E, Coraboeuf E, Mercadier JJ. Depressed transient outward current density in ventricular myocytes from cardiomyopathic Syrian hamsters of different ages. J Mol Cell Cardiol 1996;28:387-401.
23. O'Rourke B, Peng FL, Kääb S, Tunin R, Tomaselli GF, Marban E. Mechanisms of altered excitation-contraction coupling in canine tachycardia-induced heart failure: Experimental studies. Circ Res 1999;84:562-570.
24. Gwathmey JK, Copellas L, MacKinnon R, Schoen RS, Feldman MD, Grossman W, Morgan JP. Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ Res 1987;61:70-76.
25. Vermeulen JT, McGuire MA, Opthof T, Coronel R, deBakker JM, Klopping C, Janse MJ. Triggered activity and automaticity in ventricular trabeculae of failing human and rabbit hearts. Cardiovasc Res 1994;28:1547-1554.
26. Beuckelmann DJ, Näbauer M, Erdmann E. Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. Circ Res 1993;85:1046-1055.
27. Hart G. Cellular electrophysiology in cardiac hypertrophy and failure. Cardiovasc Res 1994;28:933-946.
28. Uoadid H, Albat B, Nargeot J. Calcium currents in diseased human cardiac cells. J Cardiovasc Pharmacol 1995;25:282-291.
29. 2+, exchange activity in patients with end-stage heart failure. Cardiovasc Res 1996;31:48-54.
30. Wettwer E, Amos GJ, Posival H, Ravens U. Transient outward current in human ventricular myocytes of subepicardial and subendocardial origin. Circ Res 1994;75:473-482.
31. Bryant SM, Shipsey SJ, Hart G. Regional differences in electrical and mechanical properties of myocytes from guinea-pig hearts with mild left ventricular hypertrophy. J Am Coll Cardiol 1997;35:315-323.
32. Drouin E, Charpentier F, Gauthier C, Laurent K, Le Marec H. Electrophysiologic characteristics of cells spanning the left ventricular wall of human heart: Evidence for presence of M cells. J Am Coll Cardiol 1995;26:185-192.
33. Berger RD, Kasper EK, Baughman KL, Marba E, Calkins H, Tomaselli GF. Beat-to-beat QT interval variability: Novel evidence for repolarization lability in ischemic and nonischemic dilated cardiomyopathy. Circulation 1997;96:1557-1565.
34. Barr CS, Naas A, Freeman M, Lang CC, Struthers AD. QT dispersion and sudden unexpected death in chronic heart failure. Lancet 1994;343:327-329.
35. Wilson JR, Scwartz R, Sutton M-S, Ferrao N, Horowitz LN, Reichek N, Josephson ME. Prognosis in severe heart failure: Relationships to hemodynamic measurements and ventricular ectopic activity. J Am Coll Cardiol 1983;2:403-411.
36. Singh B, Schoenbaum M, Antimisiaris, M, Takanaka C. Prognostic significance of asymptomatic ventricular arrhythmias in heart failure: Potential for mortality reduction by pharmacologic control. In: Brachmann J, Dietz R, Kubler W, eds. Heart Failure and Arrhythmias. Berlin: Springer Verlag, 1990:161-173.
37. Francis GS. Development of arrhythmias in patients with congestive heart failure: Pathophysiology, prevalence and prognosis. Am J Cardiol 1986;57:3B-10B.
38. Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, Massie BM, Colling C, Lazzeri D. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995;333:77-82.
39. Singh SN, Fisher S, Carson PE, Fletcher RD and the Veterans Affairs CHF STAT Investigators. Prevalence and significance of nonsustained ventricular tachycardia in patients with premature ventricular contractions and heart failure treated with vasodilator therapy. J Am Coll Cardiol 1998;32:942-947.
40. Echt FD, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene L, Huther L, Richardson DW, and the CAST Investigators. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781-788.
41. The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992;327:227-233.
42. Doval HC, Nul DR, Grancelli HD, Perrone SV, Bortman GR, Curiel R, for GESICA. Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994;344:493-498.
43. Singh BN. Rise and fall of guided antiarrhythmic therapy for ventricular tachycardia and fibrillation. J Cardiovasc Pharmacol Therapeut 1996;1:88-94.
44. Lazzara R. Will antiarrhythmic drug therapy guided by electrophysiology study survive in the new millenium. J Cardiovasc Pharmacol Therapeut 2001;6:1-4.
45. Cohn JN, Archibald DG, Ziesche S. Effect of vasodilator therapy on mortality in chronic congestive heart failure. N Engl J Med 1986;314:1547-1553.
46. Reiter MJ. Antiarrhythmic impact of anti-ischemic and anti-failure and other cardiovascular strategies. Card Electrophysiol Rev 2000;4:194-205.
47. Reiter MJ, Reiffel JA. The importance of beta-blockade in the therapy of serious ventricular arrhythmias. Am J Cardiol 1998;82:91-98.
48. Bayes de Luna A, Counel P, Leclerq JF. Ambulatory cardiac death: Mechanism of production of fatal arrhythmia on the basis of data from 157 cases. A Heart J 1989;117:151-158.
49. Julian DG, Camm AJ, Frangin G, Janse MJ, Munoz A, Schwartz PJ, Simon P. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 1997;349:667-674.
50. Cairns JA, Connolly SJ, Roberts R, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet 1997;349:675-682.
51. Singh BN. Antiarrhythmic actions of amiodarone: A profile of a paradoxical agent. Amer J Cardiol 1996;78:41-53.
52. Hamer AWF, Arkles LB, Johns JA. Beneficial effects of low dose amiodarone in patients with heart failure: A placebo-controlled trial. Am J Cardiol 1989;14:1768-1773.
53. Pinter, Dorian P. Interactions between implantable devices and antiarrhythmic drugs. Card Electrophysiol Rev 2000;222-226.
54. The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;337:1576-1583.
55. Connolly SJ, Gent M, Roberts RS, et al. The CIDs Investigators. Canadian Implantable Defibrillator Study (CIDS). A randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000;101:1297-1304.
56. Kuck K-H, Cappato R, Siebels, et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest. The Cardiac Arrest Study from Hamburg 2000;102:748-754.
57. Domansky M, Sakseena S, Epstein AE, et al. Relative effectiveness of the implantable cardioverter-defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular function who have survived malignant ventricular arrhythmias. AVID Investigators. Antiarrhythmics versus implantable defibrillators. J Am Coll Cardiol 1999;34:1090-1098.
58. Moss AJ, Hall WJ, Cannom DS, et al. For the Multicenter Automatic Defibrillator Implantation Investigators. Improved survival with an implantable defibrillator in patients with coronary artery disease at high risk for ventricular arrhythmias. N Eng J Med 1996;335:1933-1939.
59. Wilber DJ, Olshansky B, Moran JF, et al. Electrophysiologic testing and nonsustained ventricular tachycardia: Use and limitation in patients with coronary artery disease and impaired ventricular function. Circ 1990;82:350-352.
60. Buxton AE, Lee KL, Fisher JD, et al. For the Multicenter Unsustained Ventricular Tachycardia Trial (MUSTT). N Eng J Med 1999;341:1882-1891.
61. Moss AJ, Cannom DS, Daubert J, Hall W, Higgins S, Klein H, Wilber D, Zareba W, Brown M. Multicenter Automatic Defibrillator Trial II (MADIT II): Design and clinical protocol. Ann Noninvasive Electrocardiol 1999;22:20-27.
62. Zivin A, Bardy GH. Implantable defibrillators and antiarrhythmic drugs in patients at risk lethal arrhythmias. Am J Cardiol 1999;84:63R-68R.
63. Prystowsky EN, Benson DW Jr, Fuster VH, Robert G, Kay GN, Myerburg RJ, Naccarelli GV, Wyse DG. Management of Patients With Atrial Fibrillation: A Statement for Healthcare Professionals From the Subcommittee on Electrocardiography, American Heart Association. Circulation 1996;93(6):1262-1277.
64. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort study: The Framingham Heart Study. JAMA 1994;271:840-844.
65. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju RM. Prevalence of atrial fibrillation in elderly subjects: The Cardiovascular Health Study. Am J Cardiol 1994;74:238-241.
66. Lake RR, Cullen KJ, de Klerk NH, McCall MG, Rosman DL. Atrial fibrillation in an elderly population. Aust N Z J Med 1989;19:321-326.
67. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991;22:983-988.
68. Philips SJ, Whisnant J, O'Fallon WM, Fyre RL. Prevalence of cardiovascular disease and diabetes in residents of Rochester, Minnesota. Mayo Clin Proc 1990;65:344-359.
69. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Arch Intern Med 1995;155:469-473.
70. Deedwania PC, Singh BN, Ellenbogan K, Fisher S, Fletcher R, Singh SN for the Department of Veterans Affairs CHF-STAT Investigators. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation. Observations from the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT). Circ 1998;2574-2579.
71. Moe GK, Abildskov JA. Atrial Fibrillation as a self-sustaining arrythmia independent of focal discharge. Amer Heart J 1959;58:59-70.
72. Moe GK. On the multiple wavelet hypothesis of atrial fibrillation. Arch Int Pharmacodyn Ther 1962;140:183-188.
73. Moe GK, Rheinboldt WC, Abildskov JA. A computer model of atrial fibrillation. Amer Heart J 1964;67:200-220.
74. Allessie MA, Lammers WJEP, Bonke FIM, Hollen J. Experimental evaluation of Moe's multiple wavelet hypothesis of atrial fibrillation. In: Zipes DP, Jalife J, eds. Cardiac Electrophysiology and Arrhythmias. Orlando, FL: Grune & Stratton, 1985:265-276.
75. Wang Z, Pelletier LC, Talajic M, Nattel S. Effects of flecainide and quinidine. On human atrial potentials: Role of rate dependence and comparison with guinea pig, rabbit and dog tissues. Circulation 1990;82:274-283.
76. Wijffels MCEF, Kirchhof CJHJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation: A study in awake chronically instrumented goats. Circulation 1995;92:1954-1968.
77. Ouadid H, Albat B, Nargeot J. Calcium currents in diseased human cardiac cells. J Cardiovasc Pharmacol 1995;25:282-291.
78. Le Grand B, Hatem S, Deroubaix E, et al. Depressed transient outward and calcium currents in dilated human atria. Cardiovasc Res 1994;28:548-556.
79. + channel response to acetylcholine and to G protein - mediated activation in atrial myocytes isolated from failing human hearts. Circulation 1994;90:2213-2224.
80. + current densities and Kv1.5 expression are reduced in chronic human atrial fibrillation. Circ Res 1997;80:772-781.
81. Grogan M, Smith HC, Gersh BL, Wood DL. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol 1992;69:1570-1573.
82. Manning W, Leeman DE, Gotch PJ, Come PC. Pulsed Doppler evaluation of atrial mechanical function after electrical cardioversion of atrial fibrillation. J Am Coll Cardiol 1989;13:617-623.
83. AFFIRM Investigators. Atrial fibrillation following investigation of rhythm management the AFFIRM study design. Am J Cardiol 1997;79:1198-1202.
84. Pitt B, Zannard F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. New Eng J Med 1999;341:709-717.
85. Jais P, Shah DC, Haissaguerre M, et al. Efficacy and safety of septal and left atrial linear ablation for atrial fibrillation. Am J Cardiol 1999;84:139R-146R.
86. Feld GK. Evolution of diagnostic and interventional cardiac electrophysiology: A brief historical review. Am J Cardiol 1999;84:115R-124R.
87. Cox JL, Boineau JP, Schuessler RB, et al. Five year experience with the maze procedure atrial fibrillation. Ann Thorac Surg 1993;56:814-824.
88. Singh BN. Antiarrhythmic drugs: A re-orientation in light of recent developments in the control of disorders of rhythm. Amer J Cardiol 1998;81(6A):3D-13D.
89. Singh BN. Overview of trends in the control of cardiac arrhythmias: Past and future. Am J Cardiol 1999;84:11R-19R.
90. Singh BN. Expanding indications for the use of class III antiarrhythmic agents in patients at high risk for sudden death. J Cardiovasc Electrophysiol 1995;6:887-909.
91. Singh BN. Sotalol: Current status and expanding indications. J Cardiovasc Pharmacol Therap 1999;4:49-65;
92. Singh BN, Mody FV, Lopez B, Sarma JSM. Antiarrhythmic agents for atrial fibrillation: Focus on prolonging atrial repolarization. Amer J Cardiol 1999;84:161R-173R.
93. Singh BN. Class III antiarrhythmic drugs: Simple versus complex molecules for controlling cardiac arrhythmias. J Cardiovasc Pharmacol Therapeut 1997;2:1-6.
94. Torp-Pedersen C, Moeller M, Bloch-Thomsen P, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med 1999;341:857-865.
95. Middlekauff HR, Stevenson WG, Stevenson LW. Prognostic significance of atrial fibrillation in advanced heart failure: A study of 390 patients. Circ 1991;84:40-48.
96. Singh SN, Berk MR, Yellen LG, Zobe RG, Abrahamson D, Billing C, Satler C, Friedrich T, and the Dofetilide Atrial Fibrillation Investigators. Efficacy and safety of oral dofetilide in maintaining normal sinus rhythm in patients with atrial fibrillation/flutter: A multicenter study. Circ 1997;96(8)1:383.
97. AF-AF-CHF. Multicenter international study evaluating the value of a therapeutic strategy to restore and maintain sinus rhythm in patients with AF and CHF versus a strategy of rate control. Study initiated (Principal Investigator: D. Roy). 2001.